These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16443947)

  • 1. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021.
    Robins HI; Won M; Seiferheld WF; Schultz CJ; Choucair AK; Brachman DG; Demas WF; Mehta MP
    Neuro Oncol; 2006 Jan; 8(1):47-52. PubMed ID: 16443947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose tamoxifen and radiotherapy in patients with glioblastoma multiforme: a phase IB study.
    Muanza T; Shenouda G; Souhami L; Leblanc R; Mohr G; Corns R; Langleben A
    Can J Neurol Sci; 2000 Nov; 27(4):302-6. PubMed ID: 11097520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme.
    Del Rowe J; Scott C; Werner-Wasik M; Bahary JP; Curran WJ; Urtasun RC; Fisher B
    J Clin Oncol; 2000 Mar; 18(6):1254-9. PubMed ID: 10715295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
    Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W
    J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme.
    Langer CJ; Ruffer J; Rhodes H; Paulus R; Murray K; Movsas B; Curran W
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):113-9. PubMed ID: 11516860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.
    Coughlin C; Scott C; Langer C; Coia L; Curran W; Rubin P
    Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1351-8. PubMed ID: 11121633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article.
    Marina O; Suh JH; Reddy CA; Barnett GH; Vogelbaum MA; Peereboom DM; Stevens GH; Elinzano H; Chao ST
    J Neurosurg; 2011 Aug; 115(2):220-9. PubMed ID: 21548745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implant volume as a prognostic variable in brachytherapy decision-making for malignant gliomas stratified by the RTOG recursive partitioning analysis.
    Videtic GM; Gaspar LE; Zamorano L; Stitt LW; Fontanesi J; Levin KJ
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):963-8. PubMed ID: 11704318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial.
    Robins HI; O'Neill A; Gilbert M; Olsen M; Sapiente R; Berkey B; Mehta M
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):227-33. PubMed ID: 17882417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma.
    Li J; Wang M; Won M; Shaw EG; Coughlin C; Curran WJ; Mehta MP
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):623-30. PubMed ID: 20888136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival Analysis of Glioblastoma Multiforme.
    Witthayanuwat S; Pesee M; Supaadirek C; Supakalin N; Thamronganantasakul K; Krusun S
    Asian Pac J Cancer Prev; 2018 Sep; 19(9):2613-2617. PubMed ID: 30256068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients.
    Pichlmeier U; Bink A; Schackert G; Stummer W;
    Neuro Oncol; 2008 Dec; 10(6):1025-34. PubMed ID: 18667747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy.
    Mizoe JE; Tsujii H; Hasegawa A; Yanagi T; Takagi R; Kamada T; Tsuji H; Takakura K;
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):390-6. PubMed ID: 17459607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513.
    Fisher B; Won M; Macdonald D; Johnson DW; Roa W
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):980-6. PubMed ID: 12095566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
    Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can MRI-derived factors predict the survival in glioblastoma patients treated with postoperative chemoradiation therapy?
    Nakamura H; Murakami R; Hirai T; Kitajima M; Yamashita Y
    Acta Radiol; 2013 Mar; 54(2):214-20. PubMed ID: 23138021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710.
    Colman H; Berkey BA; Maor MH; Groves MD; Schultz CJ; Vermeulen S; Nelson DF; Mehta MP; Yung WK;
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):818-24. PubMed ID: 16887285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806).
    Alexander BM; Wang M; Yung WK; Fine HA; Donahue BA; Tremont IW; Richards RS; Kerlin KJ; Hartford AC; Curran WJ; Mehta MP
    J Neurooncol; 2013 Jan; 111(1):33-9. PubMed ID: 23086432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: benefit for selected patients.
    Fernández-Hidalgo OA; Vanaclocha V; Vieitez JM; Aristu JJ; Rebollo J; Gúrpide A; Aramendía JM; Moreno-Palanques R; Martín-Algarra S; Subirá ML; Brugarolas A
    Bone Marrow Transplant; 1996 Jul; 18(1):143-9. PubMed ID: 8832007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.